Lactulose (LL) and macrogol induced diarrhoea: at same stool weights colonic transit is slower with lactulose

Eva Fritz1, Reingard BK Rohrboech2, Johann Hammer2*, Rainer Lipp2, Christoph Hogенаuer2 and Heinz F Hammer2. 1Abteilung für Gastroenterologie und Hepatologie, Universitätsklinik für Innere Medizin IV, Vienna, Austria; and 2Medizinische Universitätsklinik Graz, Graz, Austria.

Purpose: Lactulose and macrogol are widely used as osmotic laxatives. Lactulose but not Macrogol is metabolised in the colon. To evaluate total and regional gastrointestinal transit in lactulose and macrogol induced diarrhoea.

Methods: Subjects ingested 99 g/d lactulose (osmotic load: 285 mosmol/d, n = 7) or 59 g/d macrogol 4000 (125 mosmol/d, n = 6) for three consecutive days. On day two Tc99m-radio-labelled orange-juice and a delayed-release capsule containing 1 g 111In-labelled resin-pellets were ingested. Gamma-camera images were obtained. Small intestinal transit (SIT) was calculated as time from 10% gastric emptying to 10% ingested. Gamma-camera images were obtained. Total MRT and cumulative counts (CC) appearing in stool in 24 and 36 hrs.

Results: Results are shown in the table. SIT was faster after LL without reaching significance. Although ingested osmotic loads of lactulose were double compared to macrogol, stool weights were comparable and total and distal colonic transit was prolonged.

Conclusions: Presumably transit delay in the distal colon is responsible for the compensation of large osmotic loads by allowing time for bacterial carbohydrate metabolism.

Factors that affect sedation and analgesia during colonoscopy

Brian J Gootzeit1, Zvi Alpern1, Peter F Ellis1, Bonnie J Pollack1 and Joseph C Anderson1*. 1Gastroenterology, Stony Brook University, Stony Brook, New York, United States.

Purpose: Prior knowledge of factors predictive of a difficult or painful procedure may be useful in scheduling or sedating patients undergoing colonoscopy. This study was done to assess patient satisfaction, pain, and sedation requirements during colonoscopy.

Methods: We enrolled 275 consecutive outpatient colonoscopies performed by experienced endoscopists at Stony Brook University. Data regarding gender, age, height, weight, bowel habits, pelvic surgery, and alcohol abuse (AUDIT-C) in the patient was recorded. Patients were sedated in stepwise increments with midazolam (1 mg) and fentanyl (25mcg) to a goal of spontaneous eye closure, but responsive to voice (Level II Sedation). Data recorded included procedure duration, extent of exam, sedation requirements, polypectomy, diverticular disease, and complications. Patients anonymously completed a survey regarding pain experienced (standardized 11-point box scale) and overall satisfaction (GHAA-9). Since sedation was given with incremental doses of midazolam and fentanyl, our analysis was based on the median midazolam dosage (5 mg). Chi-square analysis was performed.

Results: 119 women (avg age 57.2 yrs) and 153 men (avg age 57.2 yrs) comprised the study group. The adjusted completion rate in men was 96.1% and in women was 95.8%. Women with a BMI < 25 were more likely (75.5%) to receive more than the median dose (5mg) of Midazolam than heavier women (52.4%) (p < .01). In both BMI groups, however, women were as likely to report a pain score <3 (83.0% vs. 83.3%; p = NS). There was a similar satisfaction score in both groups. There was no statistical age difference in these two BMI groups of women. There was no such finding for BMI and sedation in men. The duration of the procedure was longer in women than in men (p < .01). Women who had a longer procedure were more likely to report pain (>=3) than women who had a shorter procedure (56.7% vs. 22.0% respectively; p < .01). Prior pelvic surgery, bowel habits or diverticular disease did not impact the procedure. Women and men >=60 years received Midazolam 5 mg significantly less often than older patients (p < .01). Three patients required a reversal of sedation and 1 patient’s procedure was complicated by bleeding.

Conclusions: 1) Women with a BMI <25 were more likely to receive greater than 5mg of Midazolam to achieve the same level of sedation, pain and satisfaction scores. 2) Women who experienced a longer procedure were more likely to report a pain score of >=3.3). Patients older than 60 years were more likely to receive less than 5mg of Midazolam. These findings may have implications for colorectal screening with colonoscopy in women, particularly those with a BMI <25.